Survival end points for full MSK cohort treated with R-CHOP induction > (R)-ICE consolidation (n = 151). (A) EFS; (B) EFS by COO; (C) OS; (D) OS by COO. MSK, Memorial Sloan Kettering; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; (R)-ICE, rituximab plus ifosfamide, carboplatin and etoposide; EFS, event-free survival; COO, cell of origin; OS, overall survival; GCB, germinal center B-cell like; CI, confidence interval; ref, reference.